LETTER TO THE EDITOR
Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving low-dose dasatinib therapy
Masahiro Imamura,
Yusuke Nakamura,
Mitsuru Sugawara,
Masahiro Imamura
Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan
Search for more papers by this authorYusuke Nakamura
Department of Pharmacy, Sapporo Hokuyu Hospital, Sapporo, Japan
Search for more papers by this authorMitsuru Sugawara
Department of Biopharmaceutical Sciences and Pharmacy, Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Search for more papers by this authorMasahiro Imamura,
Yusuke Nakamura,
Mitsuru Sugawara,
Masahiro Imamura
Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan
Search for more papers by this authorYusuke Nakamura
Department of Pharmacy, Sapporo Hokuyu Hospital, Sapporo, Japan
Search for more papers by this authorMitsuru Sugawara
Department of Biopharmaceutical Sciences and Pharmacy, Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Search for more papers by this authorNo abstract is available for this article.
References
- 1Latagliata R, Breccia M, Carmosino I et al. “Real-life” results of frontline treatment with imatinib in older patients (>65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res 2010; 34: 1472–1475.
- 2Itamura H, Kubota Y, Shindo T, Ando T, Kojima K, Kimura S. Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg. Clin Lymphoma Myeloma Leuk 2017; 17: 370–374.
- 3Imamura M. Efficacy of intermittently administered dasatinib with a reduced dose in an elderly patient with chronic myeloid leukemia. Geriatr Gerontol Int 2016; 16: 768–771.
- 4Singh N, Kumar I, Meena R, Velpandian T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 2009; 65: 545–549.
- 5D'Aldio A, Simiele M, De Francia S et al. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human peripheral blood mononuclear cell (PBMC). J Pharmer Biomed Anal 2012; 59: 109–116.
- 6Ishida Y, Murai K, Yamaguchi K et al. Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia. Eur J Clin Pharmacol 2016; 72: 185–193.
- 7Wang X, Roy A, Hochhaus AM et al. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a phase III study. Clin Pharmacol 2013; 5: 85–97.
- 8Luo FR, Yang Z, Camuso A et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006; 12: 7180–7186.
- 9Zhu QN, Hou WY, SF X et al. Ontogeny, aging, and gender-related changes in hepatic multidrug resistant protein genes in rats. Life Sci 2017; 170: 108–114.
- 10Shah NP, Kasap C, Weier C et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008; 14: 485–493.
